Board of Directors

David Meek


DAVID MEEK has served as Chairman of the Board since June 2019.  Mr. Meek is an executive biopharma leader with more than 30 years of experience in the biopharma industry, where he has held various global executive positions in major pharmaceutical and biotechnology companies. Most recently, Mr. Meek was President & CEO, Director of FerGene, a gene therapy biotech focused on cancer from January 2020 to March 2021. From July 2016 to December 2020, Mr. Meek was CEO and a member of the Board of Ipsen, a public biopharma company. Prior to joining Ipsen, he was Executive Vice-President and President of the oncology division of Baxalta prior to being acquired by Shire from July 2014 to June 2016. He spent two years as CCO of Endocyte from August 2012 to July 2014. Mr. Meek also spent eight years at Novartis as a global franchise head from January 2005 to June 2007, CEO of Novartis Canada from July 2007 to December 2009, and region head of oncology for northern, central and Eastern Europe from January 2010 to August 2012 . He began his biopharma career at Johnson & Johnson and Janssen Pharmaceuticals where he worked from July 1989 to December 2004, where he held increasingly senior levels of executive roles. Mr. Meek serves as a director for uniQure (QURE) and Stargazer Pharmaceuticals, a private biotech. Mr. Meek holds a B.A. from the University of Cincinnati.  We believe that Mr. Meek is qualified to serve on our Board because of his extensive experience and commercialization expertise within the biopharmaceutical industry as well as his experience as a director of public companies in the biopharmaceutical industry.

Manos Perros, PhD

President and Chief Executive Officer

Manos Perros, Ph.D., has served as our chief executive officer, co-founder and director since May 2015. Prior to this, Dr. Perros worked for AstraZeneca AB as vice president and head of its infection research and early development organization from 2010 to 2015 and as site head for its research center in Waltham, Massachusetts from 2012 to 2015. Prior to joining AstraZeneca, Dr. Perros served as director of the Novartis Institute for Tropical Diseases in Singapore, and prior to that, as vice-president and chief scientific officer, antivirals, at Pfizer, Inc. A chemist by training, Dr. Perros conducted his Ph.D. work in Belgium, France and Germany, and was an associate in the Biophysics department at Yale from 1993 to 1995. Dr. Perros received the PhRMA Discoverer’s Award in 2010.

Heather Berger, PhD


Heather Berger, Ph.D., has served as a member of our board of directors since August 2017. Heather is a Principal at SR One Capital Mangment; she joined in the Spring of 2019, and is on the board of Second Genome and Oren Bio, and involved in investments in Miro Bio and Design Therapeutics. Before joining SR One, Heather worked as a Principal at Sofinnova Ventures, and prior to that, as an Equity Research Analyst at two boutique Investment Banks. Heather was formally a chemist at the Astellas Research Institute focused on early stage hit-to-lead discovery, and served as Adjunct Faculty at Northwestern University. 

Heather received her Ph.D. in Chemistry at Northwestern University, MSc. in Organic Chemistry at the Weizmann Institute of Science, and B.S. from Tufts University. 

Heather Preston, MD


Heather Preston, M.D., has served as a member of our Board since August 2017. Dr. Preston has served as a managing partner at Pivotal bioVenture Partners since July 2018 and as a senior advisor to TPG Biotech, a biotechnology venture capital firm, since July 2018. Dr. Preston was previously a partner and managing director at TPG Biotech from 2005 to July 2018. Prior to joining TPG Biotech, Dr. Preston served for two years as a medical device and biotechnology venture capital investor at J.P. Morgan Partners, LLC, a private equity firm. Prior to that, she was an entrepreneur-in-residence at New Enterprise Associates, a venture capital firm, and was a leader of the pharmaceutical and medical products consulting practice at McKinsey & Co. Dr. Preston is currently serving on the boards of directors of Oxford BioMedica plc, Karuna Therapeutics, Fusion Therapeutics and Akuous Inc., all publicly held companies.  Dr. Preston has also served on the board of a number of private companies. Dr. Preston received her M.D. from the University of Oxford and a B.S. in Biochemistry from the University of London. We believe that Dr. Preston is qualified to serve on our Board because of her extensive experience in the biopharmaceutical investment industry and her scientific background.

David C. Hastings


David C. Hastings has served as a member of our board of directors since April 2018. Mr. Hastings has been Chief Financial Officer of Arbutus Biopharma, Inc. since June 2018. Mr. Hastings previously served as the Chief Financial Officer and Executive Vice President of lncyte Corporation from 2003 until 2014. During this time, Mr. Hastings oversaw all financial aspects as lncyte transitioned from research and development to commercialization, following the launch of Jakafi®(ruxolitinib). Mr. Hastings also previously served as Vice President, Chief Financial Officer and Treasurer of ArQule Inc. During his tenure at ArQule, he played an important role in ArQule's transition into a drug discovery and development organization, and in two strategic acquisitions, including the purchase of Cyclis Pharmaceuticals Inc. Prior to that, Mr. Hastings was with Genzyme Corporation as its Vice President and Corporate Controller, and with Sepracor, Inc. where he was Director of Finance.  Mr. Hastings currently serves on the board of directors of Scynexis Inc. and VBL Therapeutics Ltd.  Mr. Hastings received his B.A. in Economics at the University of Vermont. 

Howard Mayer, MD


Howard Mayer, M.D. has served as a member of our Board since August 2019.  Dr. Mayer is the executive vice president, head of research and development for Ipsen Biopharmceuticals, Inc., a position he has held since 2019.  Prior to joining Ipsen, Dr. Mayer was most recently senior vice president, chief medical officer and global head of R&D, Neuroscience Division at Shire Pharmaceuticals, or Shire Pharma, from 2018 to 2019 (acquired by Takeda Pharmaceutical Company in 2019). Previously, Dr. Mayer was senior vice president and head of global clinical development at Shire Pharma from 2013 to 2018. In this role, Dr. Mayer was responsible for global clinical development (Phase I-IV) across the hematology, immunology, oncology, genetic diseases, GI/metabolic, neuroscience and ophthalmology therapeutic areas. He was also responsible for clinical development operations, clinical pharmacology, and medical devices. Previously he served as chief medical officer at EMD Serono, a division of Merck KGaA. Prior to that, he held a variety of global roles at Pfizer Inc. over nearly eight years, including head of clinical development and medical affairs for Virology/Infectious Diseases. Prior to joining Pfizer, he served as director of infectious diseases clinical research at Bristol-Myers Squibb for five years. Dr. Mayer obtained his BA from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine in New York, which was followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at Harvard Medical School. Dr. Mayer serves on the board of Adagio Therapeutics. He also has served on the board of Autism Speaks in New England since 2011. He was honored by PharmaVoice as one of the 100 Most Inspiring People in the Life Sciences Industry in 2011 and 2017. We believe that Dr. Mayer is qualified to serve on our Board because of his extensive experience in the biopharmaceutical industry and his scientific background.